UBS Called Novo Nordisk a 'Value Trap.' Here's the Other Side of That Argument.

UBS analyst Michael Yee labeled Novo Nordisk a value trap, favoring Eli Lilly's growth prospects in the GLP-1 drug market. However, the article argues that while Eli Lilly currently leads, Novo Nordisk's strong R&D capabilities and 4.7% dividend yield make it a potential long-term turnaround story for patient investors willing to wait 5-10 years for recovery.